Created by InShot:
Definition the diversity effort on cardiology events something about uniformity in fact as betrayal eventually the effort of dancing and cardiovascular the size t2 inhibitors are used in type 2 diabetes to help to reduce the blood sugar levels they differ slightly from most anti-diabetic drugs which work by either increasing the insulin in the body or increasing
The insulin sensitivity of the cells of the body and the objective of increasing the insulin or the insulin sensitivity is to get the body to take more glucose out of the blood and to store it in the tissues and that’s how they reduce blood sugar levels however in sgl t2000 with type 2 diabetes past two decades several studies have highlighted the importance of
Intensive glucose lowering therapy blood pressure control and statin use to reduce the risk of cardiovascular complications and mortality in patients with diabetes but the long-term trends of mortality and cardiovascular outcomes of patients with type 1 or type 2 diabetes as compared with the general population are unknown in a study of patients enrolled between
1998 and 2012 in the swedish national diabetes register a total of 36 869 patients with type 1 and 457 473 patients with type 2 diabetes were included along with matched controls from the general population the outcomes that were assessed were all-cause mortality fatal coronary heart disease fatal cardiovascular disease and hospitalization for cardiovascular disease
The rate of all-cause mortality declined among those with type 1 diabetes by 29 and in matched controls by 23 a difference that was not statistically significant the rate of hospitalization for cardiovascular disease decreased by 36 percent among those with type 1 diabetes and by 9 among matched controls a decrease that was significantly greater for the diabetic
Group the rate of all-cause mortality decreased by 21 among those with type 2 diabetes and by 31 among matched controls for heart failure not only that but we wanted to also ask the question whether these drugs might be beneficial in the patients who do not have diabetes because there is experimental evidence to suggest that sglt may have benefits that are
Not glucose so to do this we study patients with heartburn and reduced ejection fraction receiving conventional therapy who were randomized to either 10 milligrams of damage were closing daily or placebo reduced the risk by 26 and that was highly statistically significant and both of the so there was a 30 reduction in the risk of western heart failure events
And indeed in heartbreak hospitalization that was statistically significant and there was an 18 reduction in the risk of cardiovascular mortality using symptoms who were enrolled in the trial for specifically a very can you just go into a little bit of detail about the study real world evidence of the effect on glycemic control with relatively simultaneous
Versus sequential initiation of basal incident insulin and glp-1 receptor agonists yes absolutely uh really what this trial was designed to investigate is in a real world setting you know what’s happening out there in clinical practice where the patient population who has a high a1c those people with a1c greater than nine percent poor glycemic rate does the
Combination of of a glp one in a basin initiated simultaneously have a better chance of achieving glycemic outcomes getting people to go as opposed to the sequential addition of those injectables meaning starting either the glp one or the basic influence and then adding that second page or hospitalization for hurt calories offended so what were some of the key
Findings of this study the key finding of the study was the fact that it was that the hypothesis was proven to be correct for that for that group of individuals who have high a1cs once they start injectable therapy the initiation simultaneously and in this study the definition of simultaneously within a one month period of time so that the individuals had to
Initiate a glp1 and a basal influx within a 30-day period of time and they were compared to individuals who had both of those agents initiated but in a longer time frame a sequential time frame so instead of within 30 days within some time within the next year so what it shows is that individuals who initiated those two agents the glp-1 and a basal insulin simultaneously
Transcribed from video
Dapagliflozin and cardiovascular outcome in type 2 diabetes By Justin lady Vera Moreira
